Table 2.
Quality of Life, Medication Satisfaction, and Tolerability Scores
| Quality of life instruments | Baseline | Change from baseline to week 4 | Change from baseline to week 12 | ||
|---|---|---|---|---|---|
| Mean (SD) | Mean (SD) | P-value | Mean (SD) | P-value | |
| *Physical health summary score (PHS) | 48.2 (11.5) | 0.015 ± 9.00 | 0.97 | 0.315 ± 9.20 | 0.79 |
| *Mental health summary score (MHS) | 50.7 (12.0) | 0.366 ± 9.07 | 0.74 | 0.313 ± 10.01 | 0.81 |
| *Augmented symptom distress module (ASDM) | 26.7 (19.8) | -2.99 ± 16.34 | 0.14 | -2.92 ± 16.48 | 0.17 |
| *Center for Epidemiology Studies-Depression (CES-D) | 14.5 (10.2) | -1.12 ± 8.00 | 0.25 | -0.753 ± 8.47 | 0.49 |
| Mean value at week 4 | Mean value at week 12 | ||||
| Medication satisfaction survey (MSS) | 9.01 ± 2.27 | NA | 8.69 ± 2.25 | NA | |
| Global Condition improvement (GCI) | 2.24 ± 3.05 | <0.0001 | 2.46 ± 3.30 | <0.0001 | |
| Therapy preference | |||||
| Prefer LPV/r tablet [No. (%)] | 55 (78%) | <0.0001 | 46 (74%) | <0.0001 | |
| Prefer LPV/r SGC [No. (%)] | 6 (9%) | 6 (10%) | |||
| No preference [No. (%)] | 9 (13%) | 10 (16%) | |||